CD4+ T-helper type 1 cytokines and trastuzumab facilitate cd8 t-cell targeting of H ER2/neu-Expressing Cancers

Cancer Immunology Research

Volumn 3, Issue 5, 2015, Pages 455-463

  Datta, Jashodeep ^a   Xu, Shuwen ^a   Rosemblit, Cinthia ^a   Smith, Jenessa B ^a   Cintolo, Jessica A ^a   Powell, Daniel J ^a   Czerniecki, Brian J ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; GAMMA INTERFERON; GAMMA INTERFERON RECEPTOR; LAPATINIB; PROGRAMMED DEATH 1 LIGAND 1; T LYMPHOCYTE RECEPTOR; TRASTUZUMAB; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA RECEPTOR; ANTINEOPLASTIC AGENT; HER2 PEPTIDE (369-377); HLA A2 ANTIGEN; PEPTIDE FRAGMENT; SMALL INTERFERING RNA; TUMOR NECROSIS FACTOR;

ARTICLE; BREAST CANCER CELL LINE; CANCER CELL; CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOLYSIS; DENDRITIC CELL; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG POTENTIATION; DRUG TARGETING; HUMAN; HUMAN CELL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TH1 CELL; GENETICS; HELPER CELL; IMMUNOLOGY; NEOPLASM; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; HLA-A2 ANTIGEN; HUMANS; INTERFERON-GAMMA; NEOPLASMS; PEPTIDE FRAGMENTS; RECEPTOR, ERBB-2; RNA, SMALL INTERFERING; T-LYMPHOCYTES, HELPER-INDUCER; TRASTUZUMAB; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84962279705     PISSN: 23266066     EISSN: 23266074     Source Type: Journal    
DOI: 10.1158/2326-6066.CIR-14-0208     Document Type: Article

References (28)

1. Menard S, Casalini P, Campiglio M, Pupa S, Agresti R, Tagliabue E. HER2 overexpression in various tumor types, focussing on its relationship to the developmentofinvasive breast cancer. Ann Oncol 2001;12 Suppl 1:S15-9.
2. Roses RE, Paulson EC, Sharma A, Schueller JE, Nisenbaum H, Weinstein S, et al. HER-2/neu overexpression as apredictor for the transition from in situ to invasive breast cancer. Cancer Epidemiol Biomarkers Prev 2009;18: 1386-9.
3. Wang GS, Zhu H, Bi SJ. Pathological features and prognosis of different molecular subtypes of breast cancer. Mol Med Rep 2012;6:779-82.
4. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005;353:1659-72.
5. Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002;20:719-26.
6. Pohlmann PR, Mayer IA, Mernaugh R. Resistance to trastuzumab in breast cancer. Clin Cancer Res 2009;15:7479-91.
7. Alexe G, Dalgin GS, Scanfeld D, Tamayo P, Mesirov JP, DeLisi C, et al. High expression of lymphocyte-associated genes in node-negative HER2+ breast cancers correlates with lower recurrence rates. Cancer Res 2007;67:10669-76.
8. Fisk B, Blevins TL, Wharton JT, Ioannides CG. Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines. J Exp Med 1995; 181:2109-17.
9. Zaks TZ, Rosenberg SA. Immunization with a peptide epitope (p369-377) from HER-2/neu leads to peptide-specific cytotoxic T lymphocytes that fail to recognize HER-2/neu +tumors. Cancer Res 1998;58:4902-8.
10. Benavides LC, Gates JD, Carmichael MG, Patil R, Holmes JP, Hueman MT, et al. The impact of HER2/neu expression level on response to the E75 vaccine: from U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02. Clin Cancer Res 2009;15:2895-904.
11. Herrmann F, Lehr HA, Drexler I, Sutter G, Hengstler J, Wollscheid U, et al. HER-2/neu-mediated regulation of components of the MHC class I antigen-processing pathway. Cancer Res 2004;64:215-20.
12. Vertuani S, Triulzi C, Roos AK, Charo J, Norell H, Lemonnier F, et al. HER-2/neu mediated down-regulation of MHC classIantigen processing prevents CTL-mediated tumor recognition upon DNA vaccination in HLA-A2 transgenic mice. Cancer Immunol Immunother 2009;58:653-64.
13. Mimura K, Ando T, Poschke I, Mougiakakos D, Johansson CC, Ichikawa J, et al. T cell recognition of HLA-A2 restricted tumor antigens is impaired by the oncogene HER2. Int J Cancer 2011;128:390-401.
14. Inoue M, Mimura K, Izawa S, Shiraishi K, Inoue A, Shiba S, et al. Expression of MHC Class I on breast cancer cells correlates inversely with HER2 expression. Oncoimmunology 2012;1:1104-10.
15. Kanai T, Totsuka T, Uraushihara K, Makita S, Nakamura T, Koganei K, et al. Blockade of B7-H1 suppresses the development of chronic intestinal inflammation. J Immunol 2003;171:4156-63.
16. Lanitis E, Smith JB, Dangaj D, Flingai S, Poussin M, Xu S, et al. A human ErbB2-specific T-cell receptor confers potent antitumor effector functions in genetically engineered primary cytotoxic lymphocytes. Hum Gene Ther 2014;25:730-9.
17. Xu S, Koski GK, Faries M, Bedrosian I, Mick R, Maeurer M, et al. Rapid high efficiency sensitization of CD8+ T cells to tumor antigens by dendritic cells leads to enhanced functional avidity and direct tumor recognition through an IL-12-dependent mechanism. J Immunol 2003;171:2251-61.
18. Lustgarten J, Theobald M, Labadie C, LaFace D, Peterson P, Disis ML, et al. Identification of Her-2/Neu CTL epitopes using double transgenic mice expressing HLA-A2.1 and human CD.8. Human Immunol 1997; 52:109-18.
19. Qin Z, Harders C, Cao X, Huber C, Blankenstein T, Seliger B. Increased tumorigenicity, but unchanged immunogenicity, of transporter for antigen presentation 1-deficient tumors. Cancer Res 2002;62:2856-60.
20. Conrad H, Gebhard K, Kronig H, Neudorfer J, Busch DH, Peschel C, et al. CTLs directed against HER2 specifically cross-react with HER3 and HER4. J Immunol 2008;180:8135-45.
21. Mendoza MC, Er EE, Blenis J. The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation. Trends Biochem Sci 2011;36:320-8.
22. Mimura K, Shiraishi K, Mueller A, Izawa S, Kua LF, So J, et al. The MAPK pathway is a predominant regulator of HLA-A expression in esophageal and gastric cancer. J Immunol 2013;191:6261-72.
23. Alba E, Albanell J, de la Haba J, Barnadas A, Calvo L, Sanchez-Rovira P, et al. Trastuzumab or lapatinib with standard chemotherapy for HER2-positive breast cancer: results from the GEICAM/2006-14 trial. Br J Cancer 2014;110:1139-47.
24. Chen J, Feng Y, Lu L, Wang H, Dai L, Li Y, et al. Interferon-gamma-induced PD-L1 surface expression on human oral squamous carcinoma via PKD2 signal pathway. Immunobiology 2012;217:385-93.
25. Soliman H, Khalil F, Antonia S. PD-L1 expression is increased in a subset of basal type breast cancer cells. PLoS One 2014;9:e88557.
26. Menard S, Tagliabue E, Campiglio M, Pupa SM. Role of HER2 gene overexpression in breast carcinoma. J Cell Physiol 2000;182: 150-62.
27. Cho HS, Mason K, Ramyar KX, Stanley AM, Gabelli SB, Denney DW Jr, et al. Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature 2003;421:756-60.
28. Ritter CA, Perez-Torres M, Rinehart C, Guix M, Dugger T, Engelman JA, et al. Human breast cancer cells selected for resistance to trastuzumab in vivo overexpress epidermal growth factor receptor and Erb B ligands and remain dependent on the Erb B receptor network. Clin Cancer Res 2007;13:4909-19.